Drug intelligence / Profile preview

STR-V005

Development stage: Preclinical
Lead developer: Starna Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

STR-V005 is a preclinical mRNA-based cancer vaccine being developed by Starna Therapeutics (also known as StarNATx). The therapeutic is designed to treat glioblastoma (GBM) and potentially other solid tumors. As an mRNA vaccine, it functions by delivering genetic sequences encoding tumor-associated antigens into the patient's cells, which then produce these antigens to stimulate a targeted T-cell mediated immune response against the cancer cells. The program is currently in the discovery and preclinical stages of development, leveraging Starna's proprietary mRNA and delivery platforms.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on STR-V005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STR-V005.

Explore the full profile